EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment

Fabio Raith iD, Daniel H O'Donovan, Clara Lemos iD, Oliver Politz iD, Bernard Haendler iD

International Journal of Molecular Sciences · 24.01.2023 · 24 (3) · 2289

DOI: 10.3390/ijms24032289 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.01.2023. Verfasst von Fabio Raith und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research & Development, Pharmaceuticals, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 254 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The reduction in androgen synthesis and the blockade of the androgen receptor (AR) function by chemical castration and AR signaling inhibitors represent the main treatment lines for the initial stages of prostate cancer. Unfortunately, resistance mechanisms ultimately develop due to alterations in the AR pathway, such as gene amplification or mutations, and also the emergence of alternative pathways that render the tumor less or, more rarely, completely independent of androgen activation. An essential oncogenic axis activated in prostate cancer is the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, as evidenced by the frequent alterations of the negative regulator phosphatase and tensin homolog (PTEN) and by the activating mutations in PI3K subunits. Additionally, crosstalk and reciprocal feedback loops between androgen signaling and the PI3K/AKT/mTOR signaling cascade that activate pro-survival signals and play an essential role in disease recurrence and progression have been evidenced. Inhibitors addressing different players of the PI3K/AKT/mTOR pathway have been evaluated in the clinic. Only a limited benefit has been reported in prostate cancer up to now due to the associated side effects, so novel combination approaches and biomarkers predictive of patient response are urgently needed. Here, we reviewed recent data on the crosstalk between AR signaling and the PI3K/AKT/mTOR pathway, the selective inhibitors identified, and the most advanced clinical studies, with a focus on combination treatments. A deeper understanding of the complex molecular mechanisms involved in disease progression and treatment resistance is essential to further guide therapeutic approaches with improved outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenProstatic NeoplasmsMaleHumansProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesAndrogensSignal TransductionTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

AKTPI3Kandrogen receptormTORprostate cancer

Substanzen

Receptors, AndrogenProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesAndrogensTOR Serine-Threonine KinasesMTOR protein, human

Autor:innen und Institutionen

  • Research & Development, Pharmaceuticals, Bayer AG, Müllerstr. 178, 13353 Berlin, Germany.
  • Bayer Research and Innovation Center, Bayer US LLC, 238 Main Street, Cambridge, MA 02142, USA.

ORCID-Profile: Fabio Raith, Clara Lemos, Oliver Politz, Bernard Haendler

Zitieren

APA

Raith, F., O'Donovan, D. H., Lemos, C., Politz, O., & Haendler, B. (2023). Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment. International Journal of Molecular Sciences, 24(3), 2289. https://doi.org/10.3390/ijms24032289

Vancouver

Raith F, O'Donovan DH, Lemos C, Politz O, Haendler B. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment. International Journal of Molecular Sciences. 2023;24(3):2289. doi:10.3390/ijms24032289

BibTeX
@article{Raith2023,
  author = {Raith, Fabio and O'Donovan, Daniel H and Lemos, Clara and Politz, Oliver and Haendler, Bernard},
  title = {Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2289},
  doi = {10.3390/ijms24032289}
}
Kostenlos starten →